BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Stelara®/Janssen/BioAdvance® (2009)

APPROVED CLINICAL INDICATIONS

(may vary within provinces – refer to local patient support program)

Crohn’s disease
Ulcerative colitis

CLASS

Monoclonal antibody interleukin (IL)-12/23 inhibitor

ACTION

Targets an overactive immune system by blocking two receptors called IL-12 and IL-23. By blocking these receptors, cells are slowed down, which reduces inflammation.